



Health
Northern Sydney
Local Health District

Facility: COM HKH MQE MV RNS RYD

REMOTE HEPATOLOGY CONSULT: HBV TREATMENT

| | | |
|-----------------------|------|---------------------------------------------------------------|
| FAMILY NAME | | MRN |
| GIVEN NAME | | <input type="checkbox"/> MALE <input type="checkbox"/> FEMALE |
| D.O.B. DD / MM / YYYY | M.O. | |
| ADDRESS | | |
| | | PH |
| M/C | FIN | |
| LOCATION / WARD | | ADM DD / MM / YYYY |

COMPLETE ALL DETAILS OR AFFIX PATIENT LABEL HERE

Hepatitis B Community s100 Prescriber Program

Initiation of patient on treatment proforma for approval by linking specialist. Please note this form is not a referral for a patient appointment.

For the Attention of the Hepatologist

Date:

Patient First Name

Patient Surname

Date of Birth:

Gender: M F

Address

Postcode

Hepatitis B History

Year of HBV Diagnosis

Transmission Risk Factor

Known Cirrhosis* Yes No

Signs of Chronic Liver Disease:

- Jaundice Hepatomegaly
 Splenomegaly Spider naevi

Evidence of **Decompensated** Liver Disease:

- Peripheral oedema Ascites
 Jaundice
 Encephalopathy Low albumin
 Variceal bleeding

* Patients with cirrhosis, hepatic decompensation or HBV/HIV co-infection should be referred to a specialist.

Co-morbidities

- Diabetes Yes No
Obesity Yes No
Hepatitis C Yes No
HIV Yes No

Social History

- Alcohol > 40 g/day Yes No
Smoker Yes No

If yes, pack years?

High Risk of Liver Disease Progression

- Male Age > 45 yrs
 Family history of HCC
 Co-infection with HIV → Refer to specialist
 Co-infection with HDV
 Presence of cirrhosis → Refer to specialist

Prior Antiviral Treatment


Has patient previously received any antiviral treatment? Yes No

If yes, which medication(s)?

- Lamivudine
 Adefovir
 Entecavir
 Tenofovir

Current Medications

(Oral, topical and inhaled: include all prescription, herbal, over the counter medications and illicit drugs)
If insufficient space, please attach a summary list of medications.



COR5178

Holes punched as per AS2828 - 2012
BINDING MARGIN - NO WRITING

CATALOGUE NUMBER NS11742A-E JAN22/V3

REMOTE HEPATOLOGY CONSULT: HBV TREATMENT



Facility: COM HKH MQE MV RNS RYD

REMOTE HEPATOLOGY CONSULT: HBV TREATMENT

| | | |
|-----------------------|------|---------------------------------------------------------------|
| FAMILY NAME | | MRN |
| GIVEN NAME | | <input type="checkbox"/> MALE <input type="checkbox"/> FEMALE |
| D.O.B. DD / MM / YYYY | M.O. | |
| ADDRESS | | |
| | | PH |
| M/C | FIN | |
| LOCATION / WARD | | ADM DD / MM / YYYY |

COMPLETE ALL DETAILS OR AFFIX PATIENT LABEL HERE

Results

Lab Results (or attach copy of results)

| Test | Date | Result | Test | Date | Result |
|----------------|------|-----------------------------------------------------------|----------------|------|-----------------------------------------------------------|
| HBsAg | | <input type="checkbox"/> Pos <input type="checkbox"/> Neg | HBeAg | | <input type="checkbox"/> Pos <input type="checkbox"/> Neg |
| *HBV DNA level | | | HBeAb | | <input type="checkbox"/> Pos <input type="checkbox"/> Neg |
| ALT | | | Creatinine | | |
| AST | | | eGFR | | |
| Bilirubin | | | Haemoglobin | | |
| Albumin | | | Platelet count | | |
| AFP | | | INR | | |

* HBV DNA is only funded once a year if patient is not on antiviral therapy.

Liver Fibrosis Assessment †**

| Test | Date | Result | Test | Date | Result |
|-----------|------|--------|------|------|--------|
| FibroScan | | | APRI | | |

† A fibrosis assessment is recommended but not required under the PBS.

APRI. AST to platelet ratio index: www.hepatitisc.uw.edu/page/clinical-calculators/apri

**People with liver stiffness on Fibroscan of ≥ 12.5 kPa or an APRI score ≥ 1.0 may have cirrhosis and should be referred to a specialist.

Phase of Chronic Hepatitis B Infection

| Phase | HBV DNA (IU/mL) | HBeAg | HBeAb | ALT | Management | My Patient's Status (tick) |
|----------------------|------------------------|-------|-------|-----------------|--------------------|----------------------------|
| HBeAg +ve CHB | | | | | | |
| Immune Tolerant | > 20 000 | + | - | Often normal | Monitor | |
| Immune Clearance | > 20 000 (fluctuating) | - | -/+ | Variable/raised | Consider treatment | |
| HbeAg -ve CHB | | | | | | |
| Immune Control | < 2000 | - | + | Normal | Monitor | |
| Immune Escape | > 2000 | - | + | Elevated | Consider treatment | |

Co-infection/Immunity Once Only Testing Required Unless High Risk

| Test | Date | Result |
|------------|------|--------------------------------------------------------|
| HCV Ab | | |
| HAV IgG Ab | | Immunisation is recommended if HAV IgG Ab not detected |
| HDV Ab | | |
| HIV Ab | | |

HCC Surveillance

| Test | Date | Result/Comment | Surveillance Interval |
|------------|------|----------------|-----------------------|
| Ultrasound | | | |

Patients with possible HCC found on surveillance should be referred for urgent specialist consultation.

Holes punched as per A52828 - 2012
BINDING MARGIN - NO WRITING



Facility: COM HKH MQE MV RNS RYD

REMOTE HEPATOLOGY CONSULT: HBV TREATMENT

| | | |
|-----------------------|------|---------------------------------------------------------------|
| FAMILY NAME | | MRN |
| GIVEN NAME | | <input type="checkbox"/> MALE <input type="checkbox"/> FEMALE |
| D.O.B. DD / MM / YYYY | M.O. | |
| ADDRESS | | |
| | | PH |
| M/C | FIN | |
| LOCATION / WARD | | ADM DD / MM / YYYY |

COMPLETE ALL DETAILS OR AFFIX PATIENT LABEL HERE

Treatment Choice (Select one prescribing choice)

Examples of When to Seek Urgent Advice/Referral:

These situations need immediate discussion and triage prioritisation with specialist service.

- | | | |
|--------------------------------------------------------------|------------------------------|-----------------------------|
| Cirrhosis (especially where suggestion of decompensation) | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Possible HCC found on surveillance | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Woman who is pregnant or planning pregnancy | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Patient requires immunosuppressive treatment or chemotherapy | <input type="checkbox"/> Yes | <input type="checkbox"/> No |

If yes to any of the above, please forward a formal referral for this patient and an appointment will be scheduled.

I plan to start treatment with (please tick): Entecavir Tenofovir

Pegylated interferon could also be considered as an option, particularly in younger people with ALT >5 x ULN who are HBeAg positive. If you think pegylated interferon is an option for this person, please discuss this with your specialist mentor before filling out the form any further.

I plan to monitor treatment with:

HBV Treatment Investigation

1. Blood

FBC, COAGS, UECr, LFT a FP
HBV sAg, sAb, HBV DNA/ Ca2+, Po4 2-

2. Urine

Urine analysis, Casts, microscopy/ Urine Sediment, Urine alb/Creat ratio, Urine prot/Creat ratio

3. Ultrasound Abdomen

Declaration by General Practitioner/Medical Officer

I declare all of the information provided above is true and correct:

| | |
|--------------------------------------------------------------------------|-----------|
| GP/MO Name | Signature |
| Provider No | Date: |
| Number of patients previously initiated on HBV treatment by GP/MO (x/5): | |
| Address | Postcode |
| Phone | Fax |
| Mobile Phone | |
| Email | |

Once completed please return both pages and the drug interactions and other attachments by email:

NSLHD-RNS-HepatologyService@health.nsw.gov.au

Office Use Only

Approval by Specialist Experienced in the Treatment of HBV

- I agree with your decision to treat this person based on the information provided above
- This patient would be more suited to HBV treatment under specialist supervision. Please forward a formal referral for this patient and an appointment will be scheduled.
- Other specialist comments to GP/MO

Specialist Name Signature

Date: